Ipamorelin: The Cleanest Growth Hormone Peptide in the Research Literature
The history of growth hormone secretagogues is a history of tradeoffs.
GHRP-6 worked, but it made you ravenously hungry and elevated cortisol. GHRP-2 was more potent, but the cortisol and prolactin stimulation made it difficult to use cleanly. Hexarelin was the most powerful option, but it desensitized rapidly and came with the same hormonal side effects as its predecessors.
Then Novo Nordisk's researchers developed ipamorelin, and the field had what it had been looking for: a compound that stimulates growth hormone release with a selectivity profile that makes everything else look blunt by comparison.
What It Is
Ipamorelin is a synthetic pentapeptide — five amino acids — with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. It belongs to the GHRP (growth hormone releasing peptide) class and was developed by Novo Nordisk in the late 1990s as part of a broader program to find clinically useful GH secretagogues.
It binds to the ghrelin receptor (technically the GH secretagogue receptor, or GHS-R1a) in the anterior pituitary, triggering the release of stored growth hormone. This mechanism is shared with other GHRPs. What distinguishes ipamorelin is what happens — and what doesn't happen — downstream.
At standard doses, ipamorelin produces robust GH release with no meaningful stimulation of cortisol, no meaningful stimulation of prolactin, and no significant hunger drive. For compounds in this class, that selectivity profile is unusual.
Molecular weight: 711.9 Da. Half-life after subcutaneous injection: approximately 2 hours.
The GH Axis: What You're Actually Manipulating
To use ipamorelin intelligently, you need to understand the system it operates within.
Growth hormone is released from the anterior pituitary in pulses — driven by a tug-of-war between two hypothalamic hormones. GHRH (growth hormone releasing hormone) pushes the pituitary to release GH. Somatostatin pulls in the opposite direction, inhibiting release. The interplay between these signals produces the pulsatile GH secretion pattern that characterizes healthy physiology.
The largest GH pulse occurs roughly 60–90 minutes after sleep onset, coinciding with the first period of slow-wave sleep. This is not a coincidence — GH release and sleep architecture are deeply linked. Which is why timing ipamorelin administration relative to sleep is more than a convenience consideration.
Ipamorelin acts by binding to ghrelin receptors in the pituitary, amplifying the GH pulse at the point of release. Crucially, it also appears to suppress somatostatin activity — simultaneously pushing the accelerator and easing off the brake.
The result is a GH pulse that is larger than it would be naturally, in a physiologically coherent pulsatile pattern that doesn't persistently suppress the natural axis.
Why Selectivity Matters
When earlier GHRPs like GHRP-6 and GHRP-2 stimulate the ghrelin receptor, they're not operating in a vacuum. The ghrelin receptor is expressed in multiple tissues, including the hypothalamus and the adrenal glands. Activation of ghrelin receptors in these tissues drives cortisol and ACTH release. That's the side effect mechanism — it's the same receptor, expressed in places you don't want stimulated.
Ipamorelin's selectivity for the pituitary ghrelin receptor over receptors in other tissues means the GH stimulus happens without meaningful activation of the cortisol axis. For athletes and researchers interested in recovery and body composition, this matters: elevated cortisol is catabolic, pro-inflammatory, and counterproductive to most of the outcomes GH peptides are used for.
The hunger stimulation mechanism follows similar logic. Ghrelin receptors in the hypothalamus and GI tract drive appetite when activated. Ipamorelin's relative selectivity means this effect is minimal at standard doses — a meaningful practical advantage over GHRP-6, which produced hunger responses significant enough to undermine protocols for people trying to manage body composition.
What the Research Shows
Ipamorelin has human clinical trial data — which puts it in a relatively small category among compounds in this space.
Novo Nordisk conducted Phase 1 and Phase 2 clinical trials, including a published study examining ipamorelin's effects on GI motility after abdominal surgery (postoperative ileus). The trials confirmed the compound's pharmacokinetic profile in humans, documented GH stimulation, and didn't identify serious adverse events. The GI motility work was based on ipamorelin's ghrelin receptor activity in gut tissue — a secondary application that emerged from the research.
The compound ultimately didn't proceed to regulatory approval. Novo Nordisk's strategic priorities shifted, and without a clear commercial pathway, Phase 3 trials were never initiated. But the existence of human pharmacokinetic data and a documented safety profile in clinical trials is meaningful context.
In terms of efficacy: studies consistently show that ipamorelin produces GH elevation of 3–10x baseline at peak, depending on dose, the individual's baseline GH axis function, and whether it's combined with a GHRH analog. Sustained use produces measurable IGF-1 elevation — the primary downstream marker of GH axis activity and the biomarker practitioners track in clinical monitoring.
The Ipamorelin + CJC-1295 Stack
Ipamorelin is frequently used alone. It's more frequently used in combination with CJC-1295, a GHRH analog.
The mechanistic rationale for this combination is precise. Ipamorelin stimulates GH release via ghrelin receptors. CJC-1295 stimulates GH release via GHRH receptors. These are entirely different receptor systems operating on the same pituitary cells. When both are activated simultaneously, the GH response is substantially amplified — not merely additive but synergistic.
The analogy: if the pituitary is a door, ipamorelin is pushing from one side while CJC-1295 is pulling from the other. The door opens further than either force alone would achieve.
Studies measuring GH area under the curve — total GH exposure over time — show the combination produces significantly greater GH response than either compound used in isolation. This is the most evidence-supported GH peptide combination available.
Protocol
Form: Lyophilized powder for reconstitution with bacteriostatic water. Standard 2–5 mg research vials. HPLC purity >98% is the quality standard.
Route: Subcutaneous injection. Well-absorbed, simple administration.
Dose: 200–300 mcg per injection is the standard research range.
Timing — and why it matters: GH release is significantly blunted by elevated insulin. Carbohydrates and protein both stimulate insulin secretion. For maximum GH response from ipamorelin, it should be administered in a fasted state — either first thing in the morning before eating, or 2–3 hours after the last meal of the day before sleep.
Pre-sleep administration is preferred by most practitioners for two reasons: it aligns with the natural GH pulse timing, and the sleep quality benefits (more on this below) are directly experienced.
Frequency:
- Once daily (pre-sleep): Most common approach
- Twice daily (AM fasted + pre-sleep): More aggressive protocols
- Three times daily: Diminishing returns, rarely justified
When combined with CJC-1295 (without DAC): Administer both simultaneously, pre-sleep. The synergistic GH response is the reason for the stack.
The Sleep Connection
One of the more consistently reported subjective effects of ipamorelin use is improved sleep quality — particularly deeper, more restorative sleep and more vivid dreams.
This isn't coincidental. GH and sleep are entangled at the level of basic physiology. The largest GH pulse occurs during slow-wave sleep. Ipamorelin amplifies that pulse. But the relationship also runs the other direction: growth hormone itself supports sleep architecture. Amplifying GH release pre-sleep appears to create a feedback loop that improves sleep quality, which in turn supports GH release.
Many users describe this as one of the more noticeable effects of a protocol — the improved recovery and energy they attribute to ipamorelin may be substantially mediated by improved sleep quality rather than direct anabolic effects.
Monitoring
If using ipamorelin seriously, serum IGF-1 measurement is the appropriate monitoring tool.
- Baseline measurement before starting
- Retest at 6–8 weeks of consistent use
- Target: upper quartile of the age-appropriate reference range
- Concern: IGF-1 consistently above the reference range suggests dose reduction
IGF-1 testing is available through standard blood labs. It's not expensive. For anyone using GH peptides with intent rather than casually, this monitoring is worth doing.
Safety
Ipamorelin's clinical trial history provides meaningful safety data beyond what animal studies alone can offer.
No significant cortisol elevation at standard doses. No meaningful prolactin stimulation. No documented hepatotoxicity. No endocrine suppression — because ipamorelin works with the existing GH axis rather than replacing it, the natural system continues to function. This is a meaningful distinction from exogenous growth hormone, which does suppress endogenous production.
Common reported effects: mild water retention (dose-dependent, related to GH's sodium-retaining effects), occasional transient tingling or flushing, headache in the first weeks of use.
The theoretical concern worth acknowledging: chronically elevated IGF-1 is associated in some epidemiological literature with increased cancer risk. The evidence for this concern at physiological IGF-1 levels (as opposed to the supraphysiological levels seen with exogenous GH abuse) is not strong, but it's the reason monitoring matters. Keep IGF-1 within the reference range, not above it.
The Honest Bottom Line
Ipamorelin is what the GHRP class was eventually going to produce: a selective, clean, well-characterized compound that does what it's supposed to do without meaningful off-target effects.
The selectivity profile — GH stimulation without cortisol, without prolactin, without significant hunger — makes it the rational starting point for any GH peptide protocol. The human clinical trial data gives it a pharmacokinetic and safety profile better established than most compounds in this space. The synergy with CJC-1295 is mechanistically coherent and practically validated by a large community of users.
The limitations are honest ones: the applications most people use it for (recovery optimization, body composition, sleep quality, anti-aging) haven't been studied in randomized controlled trials. The long-term effects of sustained GH axis stimulation in healthy adults aren't fully characterized. Monitoring matters.
But as a starting point for a researcher evaluating GH peptides — ipamorelin is the answer.
This article is for informational and educational purposes only. It does not constitute medical advice. Ipamorelin is not approved by the FDA for human use. Consult a licensed physician before considering any experimental compound.